Clinical trial technology platform Inato, based in Paris, France, has closed a $20 million Series A funding from investors including Cathay Innovation, Obvious Ventures, La Maison and Top Harvest Capital.
With the new funding, Inato will advance its diversity product offering to meet the new FDA requirements. The company will also invest in oncology-specific innovation to increase access to treatments where enrolment rates remain low.
Today, 70% of clinical research happens at the same 5% of sites, and only 5% of patients participate in a clinical trial. This lack of patient access causes trial delays and costs to skyrocket, ultimately constraining medical innovation and patient diversity.
Only 4% of clinical trials in recent years have used a representative population, impacting a drug’s efficacy and safety.
“At Inato we are reversing this trend by flipping the model and empowering research-experienced community sites to access the right trials for their team and local populations — regardless of who they are or where they live,” said Inato Co-Founder and CEO Kourosh Davarpanah.
Launched in late 2020, the Inato platform has over 2,500 community research sites that support more than 70 disease areas in more than 60 countries.
